Fate Total Current Assets vs Long Term Debt Analysis

FATE Stock

USD 4.21 0.01 0.24%

Fate Therapeutics financial indicator trend analysis is much more than just examining Fate Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fate Therapeutics is a good investment. Please check the relationship between Fate Therapeutics Total Current Assets and its Long Term Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.

Total Current Assets vs Long Term Debt

Total Current Assets vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fate Therapeutics Total Current Assets account and Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Fate Therapeutics' Total Current Assets and Long Term Debt is 0.48. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Fate Therapeutics, assuming nothing else is changed. The correlation between historical values of Fate Therapeutics' Total Current Assets and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Fate Therapeutics are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Current Assets i.e., Fate Therapeutics' Total Current Assets and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.48

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Long Term Debt

Long-term debt is a debt that Fate Therapeutics has held for over one year. Long-term debt appears on Fate Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Fate Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Fate Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.The current year's Selling General Administrative is expected to grow to about 85.5 M, whereas Issuance Of Capital Stock is projected to grow to (26.5 K).

	2021	2022	2023	2024 (projected)
Interest Expense	4.5M	5.8M	6.7M	7.1M
Depreciation And Amortization	1.3M	13.8M	18.3M	19.2M

Interest Expense Depreciation And Amortization

Fate Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.9	0.95	0.93	0.99	0.72	0.61	0.77	0.24	-0.77	0.93	0.48	0.93	0.82	0.59	0.46	0.99	0.81	0.92	0.86	0.72	0.85	0.93	0.56	-0.45	0.99
Short Long Term Debt Total	0.9		0.87	0.85	0.88	0.55	0.87	0.63	0.52	-0.93	0.8	0.25	0.96	0.65	0.5	0.46	0.88	0.88	0.86	0.82	0.82	0.96	0.87	0.83	-0.43	0.89
Other Current Liab	0.95	0.87		0.98	0.91	0.69	0.57	0.87	0.23	-0.74	0.91	0.47	0.85	0.8	0.73	0.42	0.94	0.77	0.88	0.86	0.77	0.8	0.95	0.53	-0.39	0.96
Total Current Liabilities	0.93	0.85	0.98		0.9	0.64	0.51	0.93	0.23	-0.72	0.9	0.45	0.83	0.87	0.67	0.4	0.92	0.74	0.85	0.81	0.81	0.79	0.93	0.46	-0.41	0.94
Total Stockholder Equity	0.99	0.88	0.91	0.9		0.68	0.61	0.74	0.19	-0.77	0.91	0.52	0.93	0.8	0.51	0.5	0.98	0.84	0.93	0.79	0.71	0.86	0.87	0.55	-0.54	0.98
Other Liab	0.72	0.55	0.69	0.64	0.68		0.24	0.5	-0.18	-0.26	0.62	0.67	0.56	0.49	0.84	0.28	0.78	0.44	0.55	0.77	0.12	0.4	0.75	0.23	-0.26	0.75
Property Plant And Equipment Net	0.61	0.87	0.57	0.51	0.61	0.24		0.21	0.63	-0.94	0.53	0.0	0.79	0.24	0.2	0.31	0.58	0.83	0.68	0.57	0.7	0.9	0.57	0.99	-0.33	0.59
Current Deferred Revenue	0.77	0.63	0.87	0.93	0.74	0.5	0.21		0.13	-0.48	0.77	0.39	0.63	0.92	0.59	0.31	0.76	0.48	0.66	0.65	0.73	0.55	0.8	0.14	-0.31	0.79
Net Debt	0.24	0.52	0.23	0.23	0.19	-0.18	0.63	0.13		-0.57	0.2	-0.7	0.5	0.25	-0.1	-0.05	0.13	0.23	0.17	0.39	0.56	0.49	0.34	0.6	0.22	0.16
Retained Earnings	-0.77	-0.93	-0.74	-0.72	-0.77	-0.26	-0.94	-0.48	-0.57		-0.71	-0.13	-0.88	-0.5	-0.24	-0.42	-0.73	-0.92	-0.84	-0.62	-0.88	-0.98	-0.69	-0.91	0.45	-0.75
Accounts Payable	0.93	0.8	0.91	0.9	0.91	0.62	0.53	0.77	0.2	-0.71		0.44	0.86	0.81	0.52	0.4	0.92	0.75	0.88	0.82	0.73	0.78	0.9	0.48	-0.26	0.92
Cash	0.48	0.25	0.47	0.45	0.52	0.67	0.0	0.39	-0.7	-0.13	0.44		0.23	0.27	0.54	0.44	0.58	0.47	0.53	0.25	0.05	0.25	0.35	0.0	-0.61	0.56
Non Current Assets Total	0.93	0.96	0.85	0.83	0.93	0.56	0.79	0.63	0.5	-0.88	0.86	0.23		0.75	0.39	0.38	0.9	0.84	0.85	0.82	0.78	0.94	0.87	0.73	-0.37	0.91
Non Currrent Assets Other	0.82	0.65	0.8	0.87	0.8	0.49	0.24	0.92	0.25	-0.5	0.81	0.27	0.75		0.4	0.27	0.78	0.47	0.65	0.68	0.7	0.59	0.8	0.15	-0.23	0.81
Other Assets	0.59	0.5	0.73	0.67	0.51	0.84	0.2	0.59	-0.1	-0.24	0.52	0.54	0.39	0.4		0.23	0.65	0.36	0.47	0.7	0.22	0.32	0.72	0.22	-0.2	0.64
Long Term Debt	0.46	0.46	0.42	0.4	0.5	0.28	0.31	0.31	-0.05	-0.42	0.4	0.44	0.38	0.27	0.23		0.48	0.56	0.62	0.27	0.35	0.45	0.34	0.3	-0.59	0.48
Cash And Short Term Investments	0.99	0.88	0.94	0.92	0.98	0.78	0.58	0.76	0.13	-0.73	0.92	0.58	0.9	0.78	0.65	0.48		0.82	0.92	0.84	0.66	0.83	0.92	0.54	-0.5	1.0
Common Stock Total Equity	0.81	0.88	0.77	0.74	0.84	0.44	0.83	0.48	0.23	-0.92	0.75	0.47	0.84	0.47	0.36	0.56	0.82		0.92	0.56	0.76	0.95	0.67	0.81	-0.67	0.82
Common Stock Shares Outstanding	0.92	0.86	0.88	0.85	0.93	0.55	0.68	0.66	0.17	-0.84	0.88	0.53	0.85	0.65	0.47	0.62	0.92	0.92		0.71	0.76	0.88	0.81	0.64	-0.57	0.92
Non Current Liabilities Total	0.86	0.82	0.86	0.81	0.79	0.77	0.57	0.65	0.39	-0.62	0.82	0.25	0.82	0.68	0.7	0.27	0.84	0.56	0.71		0.55	0.68	0.97	0.53	-0.01	0.84
Other Current Assets	0.72	0.82	0.77	0.81	0.71	0.12	0.7	0.73	0.56	-0.88	0.73	0.05	0.78	0.7	0.22	0.35	0.66	0.76	0.76	0.55		0.87	0.69	0.65	-0.35	0.7
Other Stockholder Equity	0.85	0.96	0.8	0.79	0.86	0.4	0.9	0.55	0.49	-0.98	0.78	0.25	0.94	0.59	0.32	0.45	0.83	0.95	0.88	0.68	0.87		0.76	0.86	-0.51	0.84
Total Liab	0.93	0.87	0.95	0.93	0.87	0.75	0.57	0.8	0.34	-0.69	0.9	0.35	0.87	0.8	0.72	0.34	0.92	0.67	0.81	0.97	0.69	0.76		0.53	-0.18	0.93
Property Plant And Equipment Gross	0.56	0.83	0.53	0.46	0.55	0.23	0.99	0.14	0.6	-0.91	0.48	0.0	0.73	0.15	0.22	0.3	0.54	0.81	0.64	0.53	0.65	0.86	0.53		-0.32	0.54
Preferred Stock Total Equity	-0.45	-0.43	-0.39	-0.41	-0.54	-0.26	-0.33	-0.31	0.22	0.45	-0.26	-0.61	-0.37	-0.23	-0.2	-0.59	-0.5	-0.67	-0.57	-0.01	-0.35	-0.51	-0.18	-0.32		-0.49
Total Current Assets	0.99	0.89	0.96	0.94	0.98	0.75	0.59	0.79	0.16	-0.75	0.92	0.56	0.91	0.81	0.64	0.48	1.0	0.82	0.92	0.84	0.7	0.84	0.93	0.54	-0.49

Click cells to compare fundamentals

Fate Therapeutics Account Relationship Matchups

Fate Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	302.3M	622.5M	921.5M	705.6M	506.2M	310.1M
Short Long Term Debt Total	26.9M	97.3M	114.8M	109.3M	103.5M	108.7M
Other Current Liab	17.5M	54.8M	45.6M	57.9M	27.5M	18.9M
Total Current Liabilities	27.8M	85.6M	81.3M	114.1M	39.1M	36.6M
Total Stockholder Equity	244.8M	384.4M	678.8M	483.9M	368.4M	210.3M
Other Liab	4.5M	58.5M	52.1M	3.9M	4.4M	4.2M
Property Plant And Equipment Net	22.8M	67.1M	70.7M	66.1M	158.5M	166.4M
Current Deferred Revenue	2.8M	21.1M	21.5M	42.2M	685K	650.8K
Net Debt	(72.9M)	(70.0M)	(18.8M)	48.0M	61.7M	64.7M
Retained Earnings	(383.5M)	(556.9M)	(769.1M)	(1.1B)	(1.2B)	(1.2B)
Accounts Payable	5.8M	6.3M	8.6M	8.3M	4.7M	4.0M
Cash	99.8M	167.3M	133.6M	61.3M	41.9M	39.8M
Non Current Assets Total	75.2M	128.1M	288.0M	203.5M	174.7M	183.4M
Non Currrent Assets Other	13.0M	32.3M	116.7M	132.5M	9.0K	8.5K
Other Assets	1.6M	95.8M	25.1M	22.5M	1.0	0.95
Cash And Short Term Investments	221.4M	482.9M	615.9M	436.2M	315.2M	224.2M
Common Stock Total Equity	65K	76K	88K	96K	110.4K	115.9K
Common Stock Shares Outstanding	68.2M	82.4M	94.7M	96.8M	98.4M	54.2M
Liabilities And Stockholders Equity	302.3M	622.5M	921.5M	705.6M	506.2M	310.1M
Non Current Liabilities Total	29.7M	152.4M	161.3M	107.6M	98.7M	63.3M
Other Current Assets	4.3M	5.9M	8.8M	27.4M	13.6M	14.3M
Other Stockholder Equity	628.2M	941.2M	1.4B	1.5B	1.6B	1.7B
Total Liab	57.5M	238.0M	242.6M	221.6M	137.8M	99.9M
Property Plant And Equipment Gross	34.2M	99.4M	70.7M	66.1M	206.1M	216.4M
Total Current Assets	227.1M	494.3M	633.4M	502.1M	331.5M	234.9M
Accumulated Other Comprehensive Income	22K	70K	(762K)	(1.9M)	15K	15.8K
Short Term Debt	1.7M	3.4M	5.6M	5.6M	6.2M	4.6M
Common Stock	76K	88K	96K	97K	99K	58.1K
Property Plant Equipment	11.4M	32.3M	162.2M	176.1M	202.5M	212.6M
Net Tangible Assets	274.5M	536.9M	678.8M	483.9M	556.5M	584.4M
Retained Earnings Total Equity	(285.4M)	(383.5M)	(556.9M)	(769.1M)	(692.2M)	(657.6M)
Short Term Investments	121.6M	315.6M	482.3M	374.9M	273.3M	159.4M
Capital Surpluse	445.8M	628.2M	941.2M	1.4B	1.7B	1.7B
Deferred Long Term Liab	1.3M	13.5M	9.9M	7.2M	8.3M	5.0M
Non Current Liabilities Other	175K	549K	702K	800K	920K	721.9K
Net Invested Capital	244.8M	384.4M	678.8M	483.9M	368.4M	381.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:

How To Invest In Fate

Details

Is Fate Stock a good investment?

Details

What is Fate Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.

You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Fate Stock analysis

When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges

Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.64)

Revenue Per Share

0.065

Quarterly Revenue Growth

(0.97)

Return On Assets

(0.21)

Return On Equity

(0.42)

The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fate Total Current Assets vs Long Term Debt Analysis

Total Current Assets vs Long Term Debt

Total Current Assets vs Long Term Debt Correlation Analysis

Correlation Coefficient

Total Current Assets

Long Term Debt

Fate Therapeutics fundamental ratios Correlations

Fate Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fate Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Fate Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Current Liabilities	+ 0.98	Other Current Liab

Other Stockholder Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.94	Property Plant And Equipment Net
Retained Earnings	- 0.93	Short Long Term Debt Total
Common Stock Total Equity	- 0.92	Retained Earnings
Property Plant And Equipment Gross	- 0.91	Retained Earnings
Other Current Assets	- 0.88	Retained Earnings